Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 150 No. 4950 (2020)

Surgical management of vascular Ehlers-Danlos syndrome and its challenges: a case report

DOI
https://doi.org/10.4414/smw.2020.20379
Cite this as:
Swiss Med Wkly. 2020;150:w20379
Published
05.12.2020

Summary

BACKGROUND

Ehlers-Danlos syndrome (EDS) is a heterogeneous group of rare inherited diseases involving connective tissue. Vascular EDS (vEDS) is associated with abnormal type III collagen, which is an essential component of skin, hollow organs and arterial walls, and causes potentially fatal visceral and arterial complications. The surgical management of these patients is challenging and should be limited to life-saving procedures.

CASE DESCRIPTION

We report a case of a 42-year-old male who presented a hemorrhagic shock due to spontaneous rupture of an ascending branch of the left colic artery. The coexisting presence of multiple abdominal vascular abnormalities suggested the diagnosis of vEDS, later confirmed by the discovery of a new missense mutation in the COL3A1 gene with pathogenic significance. The post-operative course was marked by a mechanical ileus caused by an ischemic stenosis of the descending colon. Failure of conservative management and the well-known risk of colonic perforation in these patients led to the decision to perform a diverting ileostomy.

CONCLUSION

The management of these patients is difficult, and risk-benefit assessments must be made on a case-by-case basis. Less invasive procedures should be considered whenever possible.

References

  1. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi:.https://doi.org/10.1002/ajmg.c.31552
  2. Malfait F, De Paepe A. The Ehlers-Danlos syndrome. Adv Exp Med Biol. 2014;802:129–43. doi:.https://doi.org/10.1007/978-94-007-7893-1_9
  3. Pyeritz RE. Ehlers-Danlos syndrome. N Engl J Med. 2000;342(10):730–2. doi:.https://doi.org/10.1056/NEJM200003093421009
  4. Bénistan K. Les syndromes d’Ehlers–Danlos: classification, diagnostics différentiels et traitements. Douleurs: Évaluation-Diagnostic-Traitement. 2018;19(4):161–5. doi:.https://doi.org/10.1016/j.douler.2018.07.010
  5. Pepin M, Byers P. Ehlers Danlos Syndrome Type IV. In: Gene Reviews (internet). Editors: Pagon, RA, Bird TD, Dolan CR, et al. 2019 edition. Seattle, WA: University of Washington; 2011
  6. Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014;16(12):881–8. doi:.https://doi.org/10.1038/gim.2014.72
  7. Frank M, Albuisson J, Ranque B, Golmard L, Mazzella JM, Bal-Theoleyre L, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015;23(12):1657–64. doi:.https://doi.org/10.1038/ejhg.2015.32
  8. Bade MA, Queral LA, Mukherjee D, Kong LS. Endovascular abdominal aortic aneurysm repair in a patient with Ehlers-Danlos syndrome. J Vasc Surg. 2007;46(2):360–2. doi:.https://doi.org/10.1016/j.jvs.2007.03.045
  9. Solomon JA, Abrams L, Lichtenstein GR. GI manifestations of Ehlers-Danlos syndrome. Am J Gastroenterol. 1996;91(11):2282–8.
  10. Burcharth J, Rosenberg J. Gastrointestinal surgery and related complications in patients with Ehlers-Danlos syndrome: a systematic review. Dig Surg. 2012;29(4):349–57. doi:.https://doi.org/10.1159/000343738
  11. Byard RW, Keeley FW, Smith CR. Type IV Ehlers-Danlos syndrome presenting as sudden infant death. Am J Clin Pathol. 1990;93(4):579–82. doi:.https://doi.org/10.1093/ajcp/93.4.579
  12. Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers-Danlos syndrome. Am Surg. 1996;62(10):869–73.
  13. Berney T, La Scala G, Vettorel D, Gumowski D, Hauser C, Frileux P, et al. Surgical pitfalls in a patient with type IV Ehlers-Danlos syndrome and spontaneous colonic rupture. Report of a case. Dis Colon Rectum. 1994;37(10):1038–42. doi:.https://doi.org/10.1007/BF02049321
  14. Baichi MM, Arifuddin RM, Mantry PS. Gastrointestinal bleeding in a patient with Ehlers-Danlos syndrome: an endoscopic dilemma. Dig Dis Sci. 2005;50(7):1342–3. doi:.https://doi.org/10.1007/s10620-005-2784-5
  15. Demirogullari B, Karabulut R, Demirtola A, Karabulut B, Gol IH, Aybay C, et al. A novel mutation in the vascular Ehlers-Danlos syndrome: a case presenting with colonic perforations. J Pediatr Surg. 2006;41(8):e27–30. doi:.https://doi.org/10.1016/j.jpedsurg.2006.04.009
  16. Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40–7. doi:.https://doi.org/10.1002/ajmg.c.31553
  17. Perdu J, Boutouyrie P, Lahlou-Laforêt K, Khau Van Kien P, Denarié N, Mousseaux E, et al. Syndrome d’Ehlers-Danlos vasculaire [Vascular Ehlers-Danlos syndrome]. Presse Med. 2006;35(12 Pt 2):1864–75. Article in French. doi:.https://doi.org/10.1016/S0755-4982(06)74919-3
  18. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476–84. doi:.. Correction in: Lancet. 2016;388(10044):564.https://doi.org/10.1016/S0140-6736(10)60960-9
  19. Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study. J Am Coll Cardiol. 2019;73(15):1948–57. doi:.https://doi.org/10.1016/j.jacc.2019.01.058
  20. Dubacher N, Münger J, Gorosabel MC, Crabb J, Ksiazek AA, Caspar SM, et al. Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome. Cardiovasc Res. 2020;116(2):457–65. doi:.https://doi.org/10.1093/cvr/cvz095
  21. Gorosabel MC, Dubacher N, Meienberg J, Matyas G. Vascular Ehlers-Danlos syndrome: can the beneficial effect of celiprolol be extrapolated to bisoprolol? Eur Heart J Cardiovasc Pharmacother. 2020;6(3):199–200. doi:.https://doi.org/10.1093/ehjcvp/pvz067
  22. U.S. Food and Drug Administration. 2020. FDA Warns About Increased Risk Of Ruptures Or Tears In The Aorta. Blood [online]. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics> [Accessed 2020 October 1].
  23. Watanabe A, Wada T, Tei K, Hata R, Fukushima Y, Shimada T. A Novel Gene Therapy Strategy for Vascular Ehlers-Danlos Syndrome by the Combination with RNAi Mediated Inhibition of a Mutant Allele and Transcriptional Activation of a Normal Allele. Mol Ther. 2005;11:S240. doi:.https://doi.org/10.1016/j.ymthe.2005.07.158

Most read articles by the same author(s)